

To
The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Plot C-1, Block- G
Bandra Kurla Complex, Bandra (East)
Mumbai – 400051

NSE Scrip: VILINBIO

Sub: Outcome of the Board Meeting

Pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, the Board of Directors of the Company in its Meeting held today i.e. November 12, 2025 has inter-alia considered and approved the Unaudited Standalone Financial Results of the Company for the half-year ended September 30, 2025 along with Limited Review Report.

In furtherance to the Intimation filed by the Company dated September 27, 2025 the Trading Window for trading in the Securities of the Company, which was closed from October 1, 2025 until 48 hours after the declaration of the Standalone Financial Results, shall be opened after the expiry of forty-eight hours after declaration of the said Results.

The Meeting of the Board of Directors commenced at 3:00 P.M. and concluded at 4:45 P.M.

Kindly take the above information on record.

For Vilin Bio Med Limited

Madhusudhan Yadamakanti Reddy
Managing Director
DIN: 02874260

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE HALF-YEAR ENDED SEPTEMBER 30, 2025
 (Rs. in Lakhs)

	Particulars	Half - Year Ended			Year Ended	
		30-Sep	31-Mar	30-Sep	31-Mar	31-Mar
		2025	2025	2024	2025	2024
		Unaudited	Unaudited	Unaudited	Audited	Audited
I	Income					
(a)	Revenue from Operations	966.40	1,031.67	449.32	1,480.99	1,580.49
(b)	Other Income	-	25.23	21.62	46.85	32.43
	Total Revenue	966.40	1,056.90	470.94	1,527.84	1,612.92
II	Expenses					
(a)	Cost of Materials Consumed	896.73	969.44	377.79	1,347.23	1,279.55
(b)	Purchase of Stock in Trade	-	-	-	-	-
(c)	Changes in Inventories of Stock-in-Trade, Work in Progress and Finished Goods	-	-	-	-	21.06
(d)	Employee Benefit Expenses	18.29	16.48	13.02	29.50	80.38
(e)	Finance Cost	6.77	43.58	40.93	84.51	78.58
(f)	Depreciation and Amortisation Expenses	7.45	2.99	7.45	10.44	13.01
(g)	Other Expenses	17.78	9.20	16.37	25.57	117.83
	Total Expenses	947.02	1,041.70	455.56	1,497.26	1,590.40
III	Profit / (Loss) Before Exceptional Items and Tax	19.38	15.20	15.38	30.58	22.52
	Exceptional Items	-	-	-	-	-
	Profit / (Loss) Before Tax	19.38	15.20	15.38	30.58	22.52
IV	Tax Expense:					
	(1) Current Tax	4.63	4.10	2.85	6.95	5.11
	(2) Deferred Tax	(0.42)	1.19	0.09	1.28	1.16
	Profit / (Loss) for the Period from Continuing Operations	15.17	9.91	12.44	22.35	16.24
	Profit / (Loss) from Discontinued Operations	-	-	-	-	-
	Tax Expense of Discontinued Operations	-	-	-	-	-
	Profit / (Loss) from Discontinued Operations (After Tax)	-	-	-	-	-
V	Profit / (Loss) for the Period	15.17	9.91	12.44	22.35	16.24
	Other Comprehensive Income	-	-	-	-	-
	A (i) Items that will not be reclassified to Profit or Loss	-	-	-	-	-
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	-
	B (i) Items that will be reclassified to Profit or Loss	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to Profit or Loss	-	-	-	-	-
	Total Comprehensive Income for the period (Comprising Profit / (Loss) and Other Comprehensive Income for the period)	-	-	-	-	-
VI	Earnings Per Equity Share - Basic and Diluted (In Rs.)	0.11	0.07	0.09	0.16	0.12

Registered Office: Plot No. 43, H. No. 8-2-269/S/43, 2nd Floor, Sagar Co-op Housing Society Ltd, Road No. 2, Banjara Hills Khairatabad, Hyderabad – 500034

Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar – 247667

Tel No: 040- 79618843

CIN: L24230TG2005PLC046689

GST: 36AACCV1433D1ZR

E-mail: cs@vilinbiomed.co.in

Website: www.vilinbio.com

Notes to Accounts:

1. The Financial results were reviewed by the Audit Committee and approved by the Board of Directors in their respective Meetings held on November 12, 2025.
2. Figures of previous period/year have been regrouped/recast wherever necessary to correspond with the current period.
3. The Company primarily operates in one segment i.e. manufacturing of pharmaceutical products as identified in accordance with principle enunciated in Accounting Standard 17 – Segment Reporting. Hence, separate business segment information is not applicable.
4. There are no investor complaints pending as on date.

Date: November 12, 2025
Place: Hyderabad

For Vilin Bio Med Limited

Madhusudhan Yadamakanti Reddy
Managing Director
DIN: 02874260

STATEMENT OF ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2025

(Rs. in Lakhs)

	Particulars		As at 30-Sep-2025 (Unaudited)	As at 31-Mar-2025 (Audited)
I	EQUITY AND LIABILITIES			
(A)	Shareholder's Funds			
(a)	Share Capital		1,395.00	1,395.00
(b)	Reserves and Surplus		926.52	911.35
(c)	Money received against Share Warrants		-	-
			2,321.52	2,306.25
(B)	Non-Current Liabilities			
(a)	Long-Term Borrowings		-	-
(b)	Other Long-Term Liabilities		9.02	9.44
(c)	Deferred Tax Liabilities (Net)		-	-
(d)	Other Non-Current Liabilities		-	-
			9.02	9.44
(C)	Current Liabilities			
(a)	Short Term Borrowings		45.77	257.33
(b)	Trade Payables			
	- Total Outstanding due to MSMEs		-	-
	- Total Outstanding dues other than MSMs		55.10	138.85
(c)	Other Current Liabilities		6.90	3.00
(d)	Short Term Provisions		61.52	57.83
			169.29	457.00
	Total Equity and Liabilities		2,499.83	2,772.29
II	ASSETS			
(A)	Non-Current Assets			
(a)	Property, Plant and Equipment and Intangible Assets			
	(i) Property, Plant and Equipment		306.55	128.46
	(ii) Capital work-in-progress		-	156.84
	(iii) Intangible Assets		-	-
(b)	Non - Current Investments		-	-
(c)	Deferred Tax Assets (Net)		-	-
(d)	Long Term Loans and Advances		186.42	505.84
(e)	Other Non-Current Assets		690.30	725.59
			1,183.27	1,516.73

 Registered Office: Plot No. 43, H. No. 8-2-269/S/43, 2nd Floor, Sagar Co-op Housing Society Ltd, Road No. 2, Banjara Hills
 Khairatabad, Hyderabad – 500034

Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar – 247667

Tel No: 040- 79618843

CIN: L24230TG2005PLC046689

GST: 36AACCV1433D1ZR

E-mail: cs@vilinbiomed.co.in

Website: www.vilinbio.com

(B)	Current Assets			
(a)	Inventories		612.38	441.18
(b)	Trade Receivables		554.63	630.57
(c)	Cash and Cash Equivalents		9.02	5.61
(d)	Short Term Loans and Advances		32.96	70.37
(e)	Other Current Assets		107.57	108.33
			1,316.56	1,256.06
	Total Assets		2,499.83	2,772.79

Date: November 12, 2025

Place: Hyderabad

For Vilin Bio Med Limited

Madhusudhan Yadamakanti Reddy
 Managing Director
 DIN: 02874260



CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2025		
Particulars	As at 30-Sep-2025 (Rs. In Lakhs)	As at 31-Mar-2025 (Rs. In Lakhs)
	Unaudited	Audited
Cash Flow from Operating Activities		
Net Profit Before Tax and Extra-ordinary Items	19.38	30.58
Adjustment For		
Depreciation	7.46	10.44
Foreign Exchange		
Gain or Loss on Sale of Fixed Assets		
Gain or Loss on Sale of Investment		
Finance Cost	6.77	84.51
Dividend Income		
Other adjustment of Non-Cash Item		
Other adjustment to reconcile Profit		
	14.23	94.95
Adjustment for Working Capital Change		
Adjustment for Increase/Decrease in Inventories	(171.20)	5.57
Adjustment for Increase/Decrease in Trade Receivables	75.94	(62.16)
Adjustment for Increase/Decrease in Other Current Assets	0.76	15.53
Adjustment for Increase/Decrease in Other Non-Current Assets	35.29	48.91
Adjustment for Increase/Decrease in Short Term Borrowings	(211.55)	(404.79)
Adjustment for Increase/Decrease in Long Term Loans and Advances	319.42	(39.78)
Adjustment for Increase/Decrease in Short Term Loans and Advances	37.40	47.23
Adjustment for Increase/Decrease in Trade Payables	(83.76)	(56.49)
Adjustment for Increase/Decrease in Other Current Liabilities	3.90	(8.89)
Adjustment for Provisions	3.69	(0.18)
Total Adjustment for Working Capital (B)	9.89	(455.07)
Total Adjustment to reconcile Profit (A+B)	24.12	(360.12)
Net Cash Flow from (Used in) Operations	43.50	(329.54)
Dividend Received		
Interest Received	-	(46.56)
Interest Paid		
Income Tax Paid / Refund	(4.63)	(6.95)
Net Cash Flow from (used in) operation before Extra-ordinary Items	38.87	(383.04)
Proceeds from Extra-ordinary Items		
Payment for Extra-ordinary Items		
Net Cash Flow from Operating Activities	38.87	(383.04)
Cash Flows from Investing Activities		

Registered Office: Plot No. 43, H. No. 8-2-269/S/43, 2nd Floor, Sagar Co-op Housing Society Ltd, Road No. 2, Banjara Hills
 Khairatabad, Hyderabad – 500034

Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar – 247667

Tel No: 040- 79618843

CIN: L24230TG2005PLC046689

GST: 36AACCV1433D1ZR

E-mail: cs@vilinbiomed.co.in

Website: www.vilinbio.com

Proceeds from Fixed Assets		
Proceeds from Investment or Equity Instruments		
Purchase of Fixed Assets	28.69	157.47
Purchase of Investments or Equity Instruments		
Interest Received	-	46.56
Dividend Received		
Cash Receipt from Sale of Interest in Joint Venture		
Cash Payment to acquire Interest in Joint Venture		
Cash Flow from losing Control of Subsidiaries		
Cash Payment for acquiring Control of Subsidiaries		
Proceeds from Government Grant		
Other Inflow / Outflow of Cash		
Net Cash Flow from (Used in) in Investing Activities before Extra-ordinary Items	(28.69)	(110.91)
Proceeds from Extra Ordinary Items		
Payment for Extra Ordinary Item		
Net Cash Flow from (Used in) in Investing Activities	(28.69)	(110.91)
Cash Flows from Financial Activities		
Proceeds from Issue of Shares		
Proceeds from Issuing shares for security premium		
Proceeds from Issue of Debenture / Bonds / Notes		
Redemption of Preference Shares		
Redemption of Debentures		
Proceeds from other Equity Instruments		
Proceeds from Borrowing		
Repayment of Borrowing	-	20.87
Dividend Paid		
Interest Paid	6.77	84.51
Income Tax Paid / Refund		
Net Cash Flow from (Used in) in Financial Activities before Extra-ordinary Items	(6.77)	(105.38)
Proceeds from Extra-ordinary Items		
Payment for Extra-ordinary Items		
Net Cash Flow from (Used in) in Financial Activities	(6.77)	(105.38)
Net Increase (Decrease) in Cash and Cash Equivalents before effect of Exchange Rate changes	3.41	(599.33)
Effect of Exchange Rate change on Cash and Cash Equivalents		
Net Increase (Decrease) in Cash and Cash Equivalents	3.41	(599.33)
Cash and Cash Equivalents at beginning of period	5.61	604.94
Cash and Cash Equivalents at end of period	9.02	5.61

Independent Auditor's Limited Review Report on review of Interim Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors
Vilin Bio Med Limited
Plot No: 43, H.No. 8-2-269/S/43,
Sagar Co- OP- Housing Society, Road No:2,
Banjara Hills, Hyderabad-500034

1. We have reviewed the accompanying statement of Standalone Unaudited Financial Results of Vilin Bio Med Limited (the "Company") for the Half-Year ended September 30, 2025 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the Recognition and Measurement principles laid down in the Accounting Standard – 25 "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other Accounting Principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A Review of the Interim Financial Information consists of making inquiries, primarily of the persons responsible for financial and accounting matters and applying Analytical and other Review Procedures. A Review is substantially less in scope than an Audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an Audit. Accordingly, we do not express an Audit Opinion.



5-8-352, 701, 7th Floor, Raghav Ratna Towers, Chirag Ali Lane, Abids, Hyderabad - 500 001.


Branch Office : VIJAYAWADA

Ph : +91-40-23205049, 6613 2176, 3516 5760 | E-mail : giri@ppkg.com | www.batgach.com

Associate Office at : • AHMEDABAD • BANGALORE • CHENNAI • DELHI • GUWAHATI • JAIPUR • JODHPUR • INDORE • KOLKATA
• MUMBAI • PATNA • TRIVANDRUM • SILCHAR (ASSAM)

4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the applicable Accounting Standards and other Accounting Principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PPKG & Co
Chartered Accountants
Firm Registration No. 0096558


Girdhari Lal Toshniwal
Partner
Membership No. 205140



Date: 12/11/2025
Place: Hyderabad
UDIN: 25205140 BMOPH08493